{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:58Z","timestamp":1793050978361,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 81700185"],"award-info":[{"award-number":["NSFC 81700185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nursery Talent Training Plan of Third Military Medical University","award":["2017MPRC-01"],"award-info":[{"award-number":["2017MPRC-01"]}]},{"name":"Youth Talent Training Plan of Southwest Hospital of Third Military Medical University","award":["SWH2018QNLC-01"],"award-info":[{"award-number":["SWH2018QNLC-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20<jats:sup>+<\/jats:sup> B-NHL). Recently new anti-CD20 monoclonal antibodies (mAbs) have been developed, but their efficacy and safety compared with rituximab are still controversial. We searched MEDLINE, Embase, and Cochrane Library for eligible randomized controlled trials (RCTs) that compared new anti-CD20 mAbs with rituximab in induction therapy of B-NHL. The primary outcomes are progression-free survival (PFS) and overall survival (OS), additional outcomes include event-free survival (EFS), disease-free survival (DFS), overall response rate (ORR), complete response rate (CRR) and incidences of adverse events (AEs). Time-to-event data were pooled as hazard ratios (HRs) using the generic inverse-variance method and dichotomous outcomes were pooled as odds ratios (ORs) using the Mantel\u2013Haenszel method with their respective 95% confidence interval (CI). Eleven RCTs comprising 5261 patients with CD20<jats:sup>+<\/jats:sup> B-NHL were included. Compared with rituximab, obinutuzumab significantly prolonged PFS (HR 0.84, 95% CI 0.73\u20130.96, <jats:italic>P<\/jats:italic>\u2009=\u20090.01), had no improvement on OS, ORR, and CRR, but increased the incidences of serious AEs (OR 1.29, 95% CI 1.13\u20131.48, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Ofatumumab was inferior to rituximab in consideration of ORR (OR 0.73, 95% CI 0.55\u20130.96, <jats:italic>P<\/jats:italic>\u2009=\u20090.02), and had no significant differences with rituximab in regard to PFS, OS and CRR. <jats:sup>131<\/jats:sup>I-tositumomab yielded similar PFS, OS, ORR and CRR with rituximab. <jats:sup>90<\/jats:sup>Y-ibritumomab tiuxetan increased ORR (OR 3.07, 95% CI 1.47\u20136.43, <jats:italic>P<\/jats:italic>\u2009=\u20090.003), but did not improve PFS, DFS, OS and CRR compared with rituximab. In conclusion, compared with rituximab in induction therapy of CD20<jats:sup>+<\/jats:sup> B-NHL, obinutuzumab significantly improves PFS but with higher incidence of AEs, ofatumumab decreases ORR, <jats:sup>90<\/jats:sup>Y-ibritumomab tiuxetan increases ORR.<\/jats:p>","DOI":"10.1038\/s41598-021-82841-w","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T11:38:05Z","timestamp":1612525085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Chengxin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"82841_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. Lancet 390, 298\u2013310. https:\/\/doi.org\/10.1016\/s0140-6736(16)32407-2 (2017).","journal-title":"Lancet"},{"key":"82841_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland, K. R., Armitage, J. O. & Hancock, B. W. Non-Hodgkin lymphoma. Lancet 380, 848\u2013857. https:\/\/doi.org\/10.1016\/s0140-6736(12)60605-9 (2012).","journal-title":"Lancet"},{"key":"82841_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","volume":"47","author":"SA Beers","year":"2010","unstructured":"Beers, S. A., Chan, C. H., French, R. R., Cragg, M. S. & Glennie, M. J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47, 107\u2013114. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.001 (2010).","journal-title":"Semin. Hematol."},{"key":"82841_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2217\/fon.15.57","volume":"11","author":"P Feugier","year":"2015","unstructured":"Feugier, P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin\u2019s lymphomas. Future Oncol. 11, 1327\u20131342. https:\/\/doi.org\/10.2217\/fon.15.57 (2015).","journal-title":"Future Oncol."},{"key":"82841_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1741-7015-9-36","volume":"9","author":"S Lanini","year":"2011","unstructured":"Lanini, S. et al. Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis. BMC Med. 9, 36. https:\/\/doi.org\/10.1186\/1741-7015-9-36 (2011).","journal-title":"BMC Med."},{"key":"82841_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang, S., Mukhi, N., Wang, K. & Liu, D. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5, 64. https:\/\/doi.org\/10.1186\/1756-8722-5-64 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"82841_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd3100","volume":"9","author":"MJ Keating","year":"2010","unstructured":"Keating, M. J., Dritselis, A., Yasothan, U. & Kirkpatrick, P. Ofatumumab. Nat. Rev. Drug Discov. 9, 101\u2013102. https:\/\/doi.org\/10.1038\/nrd3100 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"82841_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-018-0748-0","volume":"20","author":"CL Freeman","year":"2018","unstructured":"Freeman, C. L. & Sehn, L. Anti-CD20 directed therapy of B cell lymphomas: Are new agents really better?. Curr. Oncol. Rep. 20, 103. https:\/\/doi.org\/10.1007\/s11912-018-0748-0 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"82841_CR9","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.2217\/fon-2017-0275","volume":"13","author":"ZN Soe","year":"2017","unstructured":"Soe, Z. N. & Allsup, D. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol. 13, 2611\u20132628. https:\/\/doi.org\/10.2217\/fon-2017-0275 (2017).","journal-title":"Future Oncol."},{"key":"82841_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","volume":"130","author":"G Cartron","year":"2017","unstructured":"Cartron, G. & Watier, H. Obinutuzumab: What is there to learn from clinical trials?. Blood 130, 581\u2013589. https:\/\/doi.org\/10.1182\/blood-2017-03-771832 (2017).","journal-title":"Blood"},{"key":"82841_CR11","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan, J. M. L., Wong, J., Northcott, M. J. & Opat, S. Anti-CD20 monoclonal antibodies: Reviewing a revolution. Hum. Vaccines Immunother. 14, 2820\u20132841. https:\/\/doi.org\/10.1080\/21645515.2018.1508624 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"82841_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai, K., Klein, C., Oya, N. & Fingerle-Rowson, G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv. Ther. 34, 324\u2013356. https:\/\/doi.org\/10.1007\/s12325-016-0451-1 (2017).","journal-title":"Adv. Ther."},{"key":"82841_CR13","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","volume":"28","author":"TM Illidge","year":"2010","unstructured":"Illidge, T. M. Radioimmunotherapy of lymphoma: A treatment approach ahead of its time or past its sell-by date?. J. Clin. Oncol. 28, 2944\u20132946. https:\/\/doi.org\/10.1200\/JCO.2009.26.8748 (2010).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","volume":"105","author":"D Rizzieri","year":"2016","unstructured":"Rizzieri, D. Zevalin(\u00ae) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?. Crit. Rev. Oncol. Hematol. 105, 5\u201317. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.008 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"82841_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16. https:\/\/doi.org\/10.1186\/1745-6215-8-16 (2007).","journal-title":"Trials"},{"key":"82841_CR16","first-page":"CD009211","volume":"6","author":"J Zacher","year":"2014","unstructured":"Zacher, J., Kasenda, B., Engert, A. & Skoetz, N. The role of additional radiotherapy for primary central nervous system lymphoma. Cochrane Database Syst. Rev. 6, CD009211 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"82841_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions 2nd edn. (Wiley, Chichester, 2019).","edition":"2"},{"key":"82841_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2017-02-766691","volume":"130","author":"RO Casasnovas","year":"2017","unstructured":"Casasnovas, R. O. et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET Driven strategy in Aa-IPI 1\u20133 DLBCL patients (< 60 years): Third planned interim and final analyses of the gained trial. Blood 130, 190 (2017).","journal-title":"Blood"},{"key":"82841_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus, R. et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377, 1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598 (2017).","journal-title":"N. Engl. J. Med."},{"key":"82841_CR20","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/jco.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann, W. et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J. Clin. Oncol. 36, 2395\u20132404. https:\/\/doi.org\/10.1200\/jco.2017.76.8960 (2018).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-99-115167","volume":"132","author":"W Townsend","year":"2018","unstructured":"Townsend, W. et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: Four-year results from the phase III GALLIUM study. Blood 132, 1597 (2018).","journal-title":"Blood"},{"key":"82841_CR22","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/jco.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn, L. H. et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-Hodgkin lymphoma: Final analysis of the GAUSS study. J. Clin. Oncol. 33, 3467\u20133474. https:\/\/doi.org\/10.1200\/jco.2014.59.2139 (2015).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR23","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/jco.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo, U. et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 35, 3529\u20133537. https:\/\/doi.org\/10.1200\/jco.2017.73.3402 (2017).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR24","first-page":"102","volume":"101","author":"DG Maloney","year":"2016","unstructured":"Maloney, D. G. et al. A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab containing therapy (HOMER): Results of the interim analysis. Haematologica 101, 102 (2016).","journal-title":"Haematologica"},{"key":"82841_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/jco.2016.69.0198","volume":"35","author":"GW van Imhoff","year":"2017","unstructured":"van Imhoff, G. W. et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J. Clin. Oncol. 35, 544\u2013551. https:\/\/doi.org\/10.1200\/jco.2016.69.0198 (2017).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR26","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/jco.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose, J. M. et al. Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial. J. Clin. Oncol. 31, 1662\u20131668. https:\/\/doi.org\/10.1200\/jco.2012.45.9453 (2013).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/10428194.2014.927461","volume":"56","author":"RC Quackenbush","year":"2015","unstructured":"Quackenbush, R. C., Horner, T. J., Williams, V. C., Giampietro, P. & Lin, T. S. Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab. Leuk. Lymphoma 56, 779\u2013781. https:\/\/doi.org\/10.3109\/10428194.2014.927461 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"82841_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press, O. W. et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J. Clin. Oncol. 31, 314\u2013320. https:\/\/doi.org\/10.1200\/JCO.2012.42.4101 (2013).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/jco.2017.74.5083","volume":"36","author":"M Shadman","year":"2018","unstructured":"Shadman, M. et al. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: Long-term follow-up of phase III randomized study SWOG-S0016. J. Clin. Oncol. 36, 697\u2013703. https:\/\/doi.org\/10.1200\/jco.2017.74.5083 (2018).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR30","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood.V126.23.3192.3192","volume":"126","author":"IF Khouri","year":"2015","unstructured":"Khouri, I. F. et al. In-vivo purging with rituximab (r) followed by Z\/BEAM vs BEAM\/R autologous stem cell conditioning for relapsed diffuse large b-cell lymphoma (DLBCL) patients (pts): Mature results from a combined analysis of 3 trials. Blood 126, 3192 (2015).","journal-title":"Blood"},{"key":"82841_CR31","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/jco.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig, T. E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J. Clin. Oncol. 20, 2453\u20132463. https:\/\/doi.org\/10.1200\/jco.2002.11.076 (2002).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","volume":"5","author":"LI Gordon","year":"2004","unstructured":"Gordon, L. I. et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5, 98\u2013101 (2004).","journal-title":"Clin. Lymphoma"},{"key":"82841_CR33","first-page":"5603","volume":"130","author":"GF Guzauskas","year":"2017","unstructured":"Guzauskas, G. F. et al. Is obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy for previously untreated follicular lymphoma patients cost-effective in the US? Blood 130, 5603 (2017).","journal-title":"Blood"},{"key":"82841_CR34","first-page":"A110","volume":"20","author":"LA Sun","year":"2017","unstructured":"Sun, L. A. & Carlson, J. J. Cost-utility of obinutuzumab in previously untreated follicular lymphoma. Value Health 20, A110-a111 (2017).","journal-title":"Value Health"},{"key":"82841_CR35","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles, G. et al. Rituximab in B-cell hematologic malignancies: A review of 20 years of clinical experience. Adv. Ther. 34, 2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x (2017).","journal-title":"Adv. Ther."},{"key":"82841_CR36","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359\u20137368. https:\/\/doi.org\/10.1038\/sj.onc.1206939 (2003).","journal-title":"Oncogene"},{"key":"82841_CR37","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/jco.2010.27.9836","volume":"28","author":"BD Cheson","year":"2010","unstructured":"Cheson, B. D. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28, 3525\u20133530. https:\/\/doi.org\/10.1200\/jco.2010.27.9836 (2010).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4049\/jimmunol.0900632","volume":"183","author":"AW Pawluczkowycz","year":"2009","unstructured":"Pawluczkowycz, A. W. et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183, 749\u2013758. https:\/\/doi.org\/10.4049\/jimmunol.0900632 (2009).","journal-title":"J. Immunol."},{"key":"82841_CR39","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1200\/jco.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher, R. I. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J. Clin. Oncol. 23, 7565\u20137573. https:\/\/doi.org\/10.1200\/jco.2004.00.9217 (2005).","journal-title":"J. Clin. Oncol."},{"key":"82841_CR40","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jamainternmed.2014.5756","volume":"174","author":"V Prasad","year":"2014","unstructured":"Prasad, V. The withdrawal of drugs for commercial reasons: The incomplete story of tositumomab. JAMA Intern. Med. 174, 1887\u20131888. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5756 (2014).","journal-title":"JAMA Intern. Med."},{"key":"82841_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood.V122.21.369.369","volume":"122","author":"A Lopez-Guillermo","year":"2013","unstructured":"Lopez-Guillermo, A. et al. A randomized phase II study comparing consolidation with a single dose of 90y ibritumomab tiuxetan (Zevalin\u00ae) (Z) Vs. maintenance with rituximab (R) for two years in patients with newly diagnosed Follicular Lymphoma (FL) responding to R-CHOP. Preliminary results at 36 months from randomization. Blood 122, 21 (2013).","journal-title":"Blood"},{"key":"82841_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. & George, A. J. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325\u2013338. https:\/\/doi.org\/10.1038\/nrd3003 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"82841_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi, P. M., Tawbi, H. A., Oddis, C. V. & Kulkarni, H. S. Clinical review: Serious adverse events associated with the use of rituximab\u2014a critical care perspective. Crit. Care 16, 231. https:\/\/doi.org\/10.1186\/cc11304 (2012).","journal-title":"Crit. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82841-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82841-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82841-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:24:08Z","timestamp":1670037848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82841-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82841"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82841-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3255"}}